FDA Approved: PLUVICTO — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved Pluvicto (lutetium Lu-177 vipivotide tetraxetan) from Novartis as an original approval for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

ORIG AP for PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN)